Skip to content

Study · Measured the body's own peptide · 2011

1 result

Pretreatment with lipopolysaccharide modulates innate immunity in corneal fibroblasts challenged with Aspergillus fumigatus.

Xiaoyan Zhang, Xinyi Wu, Li Gao

Innate immunity19 Mar 2010Cited by 10 (Europe PMC)

PMID20305039 (opens in a new tab)DOI10.1177/1753425910365364 (opens in a new tab)PepBankPUB-20305039
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Natural levels measured1

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01LabEndogenous levelIn vitro (cells)Mechanism

    In human stroma fibroblasts challenged with A. fumigatus, pretreatment with low-dose LPS increased the cells' own thymosin beta‑4 expression.

    In plain wordsIn human cornea-type cells, low-dose LPS pretreatment raised the cells' own thymosin beta‑4 levels after a fungal challenge.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseThymosin beta-4 expression after LPS pretreatment and A. fumigatus challenge
    Study

    humann: not reported in source

    telomerase-immortalized human stroma fibroblasts (THSFs)
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    elevated expression of antimicrobial peptides, such as CC chemokine-ligand 20 (CCL20) and thymosin β4 (Tβ4)
    1 context sentence
    Summary · context
    The THSFs were pretreated with low-dose LPS for various times and then challenged with A. fumigatus hyphae.

    This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 01:52 UTC

    Study results updated

  2. Version 1

    12 Oct 2026, 18:17 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.